ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Upcoming Meeting

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Oct 07, 2021 8:32am

197 Views

Post# 33978980

RE:RE:RE:Upcoming Meeting

Was hoping our share price would be a lot higher before we began this process. My limited understanding is that an entry level price on the Nasdaq is 5.00$ so if we remain at this share price we're most likely looking at 25:1 minimum consolidation, but I would like someone more knowledgeable in the field to give their opinion.
I'm still hoping that positive news near term will push SP higher.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario